StreetInsider.com News Articles

Ainos reports 3 billion chemical data points collected by AI Nose

Fri, 30 Oct 2026 09:01:05 -0400

Ainos, Inc. (NASDAQ: AIMD, NASDAQ: AIMDW) announced that its AI Nose platform has accumulated more than 3 billion real-world chemical data points, according to a company statement. The figure represents more than triple the 1 billion milestone the company reported in September.

The AI Nose platform converts chemical signals into data that customers can use to monitor environmental changes, investigate anomalies and maintain historical records in factory settings. Ainos says the accumulated data supports training and validation of its Scent AI software and refinement of system performance.

The company states the platform is deployed in advanced packaging facilities, where chemical monitoring is

Ainos reports 3 billion chemical data points collected by AI Nose

Fri, 30 Oct 2026 09:01:05 -0400

The company states the platform is deployed in advanced packaging facilities, where chemical monitoring is

Ainos reports 3 billion chemical data points collected by AI Nose

Fri, 30 Oct 2026 09:01:05 -0400

The company states the platform is deployed in advanced packaging facilities, where chemical monitoring is

Ainos reports 3 billion chemical data points collected by AI Nose

Fri, 30 Oct 2026 09:01:05 -0400

The company states the platform is deployed in advanced packaging facilities, where chemical monitoring is

Ainos Surpasses 3 Billion Real-World Chemical Data Points, Advancing Chemical Intelligence for Smart Factories

Fri, 30 Oct 2026 09:00:00 -0400

HOUSTON, TX / ACCESS Newswire / October 30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that its AI Nose platform has accumulated more than 3 billion real-world chemical data points, surpassing three times the 1 billion milestone announced in September. The rapid expansion of its real-world dataset strengthens the foundation of the Company's Chemical Intelligence platform, supporting product improvement, deeper customer engagement and future commercial opportunities.

Ongoing factory operations connect customer applications with technology development. AI Nose converts chemical signals into information customers can track and analyze to monitor

Ainos Surpasses 3 Billion Real-World Chemical Data Points, Advancing Chemical Intelligence for Smart Factories

Fri, 30 Oct 2026 09:00:00 -0400

Ongoing factory operations connect customer applications with technology development. AI Nose converts chemical signals into information customers can track and analyze to monitor

Ainos Surpasses 3 Billion Real-World Chemical Data Points, Advancing Chemical Intelligence for Smart Factories

Fri, 30 Oct 2026 09:00:00 -0400

Ongoing factory operations connect customer applications with technology development. AI Nose converts chemical signals into information customers can track and analyze to monitor

Ainos Surpasses 3 Billion Real-World Chemical Data Points, Advancing Chemical Intelligence for Smart Factories

Fri, 30 Oct 2026 09:00:00 -0400

Ongoing factory operations connect customer applications with technology development. AI Nose converts chemical signals into information customers can track and analyze to monitor

Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment

Wed, 30 Sep 2026 09:00:00 -0400

HOUSTON, TX / ACCESS Newswire / September 30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed the required data delivery and technology transfer under its VELDONA® license agreement, triggering a $600,000 initial license payment. The licensing partner confirmed completion in writing on September 29. Payment is due within 15 business days under the agreement.

The delivery includes clinical and regulatory materials for Sjögren's disease and thrombocytopenia, providing a foundation for the partner's continued development work in autoimmune and hematologic diseases. The initial payment is part of

Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment

Wed, 30 Sep 2026 09:00:00 -0400

Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment

Wed, 30 Sep 2026 09:00:00 -0400

Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment

Wed, 30 Sep 2026 09:00:00 -0400

Ainos delivers 1,400 AI Nose units to ASE under $2.1M contract

Tue, 29 Sep 2026 08:03:03 -0400

Ainos, Inc. (NASDAQ: AIMD) announced it has completed delivery of 1,400 AI Nose systems to ASE Technology Holding Co. under a $2.1 million, three-year agreement, according to a company statement.

The delivery covers AI Nose hardware and subscription-based services for ASE's semiconductor packaging and testing operations. Ainos previously disclosed receipt of approximately $350,000 in customer prepayments under the contract. The company said it expects the delivery to contribute to third-quarter 2026 revenue, though final amounts remain subject to quarter-end closing.

ASE's deployment of the first-phase systems across multiple locations, primarily in advanced packaging processes, has prompted discussions for a larger second-phase deployment.

Ainos delivers 1,400 AI Nose units to ASE under $2.1M contract

Tue, 29 Sep 2026 08:03:03 -0400

Ainos, Inc. (NASDAQ: AIMD) announced it has completed delivery of 1,400 AI Nose systems to ASE Technology Holding Co. under a $2.1 million, three-year agreement, according to a company statement.

ASE's deployment of the first-phase systems across multiple locations, primarily in advanced packaging processes, has prompted discussions for a larger second-phase deployment.

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract

Tue, 29 Sep 2026 08:00:00 -0400

HOUSTON, TX / ACCESS Newswire / September 29, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed delivery of all 1,400 AI Nose systems to ASE Technology Holding Co., Ltd. ("ASE") under the announced $2.1 million, three-year agreement. The completed delivery marks a major commercial milestone for Ainos' Chemical Intelligence platform in advanced back-end semiconductor manufacturing. Management expects the delivery to contribute to revenue beginning in the third-quarter 2026 revenue, advancing the Company's previously communicated second-half commercialization outlook.

ASE's experience deploying the first-phase systems across different locations,

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract

Tue, 29 Sep 2026 08:00:00 -0400

ASE's experience deploying the first-phase systems across different locations,

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract

Tue, 29 Sep 2026 08:00:00 -0400

ASE's experience deploying the first-phase systems across different locations,

Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year Contract

Tue, 29 Sep 2026 08:00:00 -0400

ASE's experience deploying the first-phase systems across different locations,

Ainos outlines VELDONA license terms with $600K initial fee

Mon, 28 Sep 2026 08:02:29 -0400

Ainos, Inc. (NASDAQ: AIMD, NASDAQ: AIMDW) has provided additional details on its VELDONA® License Agreement, originally announced Sept. 24, 2026, including payment terms and a breakdown of potential revenue streams.

The company expects to receive an initial license fee of $600,000 within 15 business days after applicable payment conditions are met, with no dependency on future clinical trial outcomes or marketing approval.

Under the agreement, a pharmaceutical development partner will fund and execute clinical and regulatory activities for two initial licensed indications: Sjögren's disease and thrombocytopenia. Ainos retains 25% of applicable net sublicensing revenue, which may include upfront payments, option fees, milestones

Ainos outlines VELDONA license terms with $600K initial fee

Mon, 28 Sep 2026 08:02:29 -0400

Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence

Mon, 28 Sep 2026 08:00:00 -0400

HOUSTON, TX / ACCESS Newswire / September 28, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today detailed the financial and strategic benefits of the VELDONA® License Agreement announced on September 24, 2026 (the "Agreement"). Ainos expects to complete the agreed contractual delivery shortly, with an initial license fee of $600,000 payable within 15 business days after the applicable payment conditions are satisfied. This payment does not depend on completion of future clinical trials or receipt of marketing approval.

The pharmaceutical development partner identified in the September 24 announcement (the "licensee") will

Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence

Mon, 28 Sep 2026 08:00:00 -0400

The pharmaceutical development partner identified in the September 24 announcement (the "licensee") will

Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence

Mon, 28 Sep 2026 08:00:00 -0400

The pharmaceutical development partner identified in the September 24 announcement (the "licensee") will

Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence

Mon, 28 Sep 2026 08:00:00 -0400

The pharmaceutical development partner identified in the September 24 announcement (the "licensee") will

Ainos signs VELDONA license deal with BioPhoenix worth up to $10M

Thu, 24 Sep 2026 08:02:32 -0400

Ainos, Inc. (NASDAQ: AIMD, NASDAQ: AIMDW) has entered into a license agreement with BioPhoenix Co., Ltd. for its VELDONA platform, establishing a collaboration framework with a potential aggregate value of $10 million, according to a company statement.

Under the agreement, BioPhoenix receives an exclusive worldwide license to VELDONA for two initial indications — Sjögren's disease and thrombocytopenia — covering research, development, manufacturing, regulatory activities and commercialization. The $10 million framework includes an initial license fee, conditional consideration for licenses covering 15 additional indications, and a one-time fee triggered by BioPhoenix's first sublicense to a third party.

The company noted that the $10